IP Library Granted Patent US 8,105,779
Granted Patent B2
US 8,105,779 · App. 13/183,312 · Granted Jan 31, 2012

Compositions and methods for detecting the presence of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,105,779
App. No.
13/183,312
Granted
Jan 31, 2012
Kind
B2
Abstract

The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from Cryptosporidium organisms, and Cryptosporidium parvum organisms in particular, which are useful for determining the presence of Cryptosporidium organisms in a test sample. The oligonucleotides of the present invention include hybridization assay probes, helper probes and amplification primers. The present invention further describes a novel method for obtaining purified ribonucleic acid from viable oocysts.

Claims (21)

1. A hybridization assay probe comprising a detectable label and the base sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 or SEQ ID NO:18, wherein the probe hybridizes to nucleic acid derived from Cryptosporidium parvum under stringent conditions to form a probe:target hybrid stable for detection, and wherein the probe does not hybridize to nucleic acid derived from Cryptosporidium muris, Cryptosporidium baileyi , or Cryptosporidium wrairi to form a probe:non-target hybrid stable for detection under the stringent conditions.

2. The probe of claim 1 , wherein the probe is up to 27 bases in length.

3. The probe of claim 1 , wherein the base sequence of the probe consists of the base sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 or SEQ ID NO:18.

4. The probe of claim 1 , wherein the probe comprises at least one base sequence that does not stably hybridize to nucleic acid derived from Cryptosporidium parvum, Cryptosporidium muris, Cryptosporidium baileyi , or Cryptosporidium wrairi under the stringent conditions.

5. The probe of claim 4 , wherein the probe comprises a pair of base sequences that hybridize to each other when the probe is not hybridized to nucleic acid derived from Cryptosporidium parvum under the stringent conditions.

6. The probe of claim 5 , wherein the probe comprises a group of interacting labels.

7. The probe of claim 6 , wherein the interacting labels include a luminescent label and a quencher label.

8. The probe of claim 1 , wherein the probe includes at least one ribonucleotide modified to include a 2′-O-methyl substitution to the ribofuranosyl moiety.

9. The probe of claim 1 , wherein a pseudo peptide backbone joins at least a portion of the bases of the probe.

10. The probe of claim 1 , wherein the stringent conditions comprise 50 mM succinic acid, 1% (w/v) LLS, 7.5 mM aldrithiol-2, 0.6 M LiCl, 115 mM LiOH, 10 mM EDTA, 10 mM EGTA, 1.5% (v/v) ethyl alcohol (absolute), pH to 4.7, at a temperature of about 60° C.

11. A method for determining the presence of Cryptosporidium parvum in a test sample, the method comprising the steps of:

contacting the test sample with the probe of claim 1 under stringent conditions; and

determining whether the probe:target hybrid has formed under the stringent conditions as an indication of the presence of Cryptosporidium parvum in the test sample.

12. The method of claim 11 , wherein the probe is up to 27 bases in length.

13. The method of claim 11 , wherein the base sequence of the probe consists of the base sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14 or SEQ ID NO:18.

14. The method of claim 11 , wherein the probe comprises at least one base sequence that does not stably hybridize to nucleic acid derived from Cryptosporidium parvum, Cryptosporidium muris, Cryptosporidium baileyi , or Cryptosporidium wrairi under the stringent conditions.

15. The method of claim 14 , wherein the probe comprises a pair of base sequences that hybridize to each other when the probe is not hybridized to nucleic acid derived from Cryptosporidium parvum under the stringent conditions.

16. The method of claim 15 , wherein the probe comprises a group of interacting labels.

17. The method of claim 16 , wherein the interacting labels include a luminescent label and a quencher label.

18. The method of claim 11 , wherein the probe includes at least one ribonucleotide modified to include a 2′-O-methyl substitution to the ribofuranosyl moiety.

19. The method of claim 11 , wherein a pseudo peptide backbone joins at least a portion of the bases of the probe.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2011
From: CUNNINGHAM, MELISSA M; STULL, PAUL D; WEISBURG, WILLIAM G
To: GEN-PROBE INCORPORATED
Reel/Frame 027147/0608 →